A Phase 1 Dose Escalation Study of OMP-59R5 in Subjects With Solid Tumors.

Trial Profile

A Phase 1 Dose Escalation Study of OMP-59R5 in Subjects With Solid Tumors.

Completed
Phase of Trial: Phase I

Latest Information Update: 27 Sep 2016

At a glance

  • Drugs Tarextumab (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors OncoMed Pharmaceuticals
  • Most Recent Events

    • 09 Apr 2013 Status changed from active, no longer recruiting to completed, according to OncoMed Biosciences.
    • 28 Mar 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 28 Mar 2013 Planned end date changed from 1 Jun 2013 to 1 Aug 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top